Of note, several reports indicate that regorafenib can be a substrate for P-gp and BCRP, thereby suggesting its ability to sensitize cancer cells to certain chemotherapies acting as a competitive ABC inhibitor [246,247]. This evidence concerns the gene ABCG2 and cancer.